Blue Jet Healthcare Limited has been awarded the EcoVadis Silver Medal for its sustainability management practices, placing it in the top 15% of companies evaluated globally. The company achieved an EcoVadis Sustainability Score of 77 out of 100, reflecting its performance in Environment, Labor and Human Rights, Ethics, and Sustainable Procurement. This recognition underscores the company's commitment to embedding environmental, social, and governance (ESG) principles into its operations.

EcoVadis assessed the company across four key themes: environment, labor and human rights, ethics, and sustainable procurement. The Silver Medal designation indicates a 90th percentile ranking in sustainability performance. This achievement marks a progression from the EcoVadis Committed Badge the company previously earned.

Management Commentary

Mr. Shiven Akshay Arora, Managing Director, stated that the award marks a significant milestone in the company's sustainability journey. He noted that the recognition reflects meaningful progress in strengthening environmental, social, ethical, and governance practices across operations. He attributed the achievement to the collective efforts of employees, business partners, and stakeholders.

Sustainability Scorecard

Company Profile

Established in 1968, blue jet healthcare is a manufacturer of specialty chemicals and pharmaceutical intermediates serving global pharmaceutical companies. The company operates with a focus on quality, compliance, and governance-led growth.

Blue Jet Healthcare has successfully closed its Qualified Institutions Placement (QIP), allotting 15,810,276 equity shares at an issue price of ₹506.00 per share, aggregating ₹8000.00 million. The allotment includes a premium of ₹504.00 per share over the face value of ₹2, incorporating a discount of ₹25.70, or 4.83%, to the floor price of ₹531.70. The Investment and Finance Committee approved the closure and final allocation during a meeting held on July 9, 2026.

QIP Allocation Details

The committee approved the allocation of shares to eligible qualified institutional buyers upon receipt of application forms and funds in the escrow accounts. The issue price was determined in consultation with the book running lead managers, utilizing the maximum permissible discount under the regulations.

Pursuant to the allotment, the paid-up equity share capital of the company has increased from ₹346,930,850 consisting of 173,465,425 equity shares of ₹2 each to ₹378,551,402 consisting of 189,275,701 equity shares of ₹2 each.

Major Allottees

Shamyak Investment Private Limited emerged as the largest subscriber, receiving 5,434,785 shares, which represents 34.38% of the total issue size. The shareholding pattern of the company, before and after the issue, will be submitted along with the listing application.

Regulatory Framework and Approvals

The placement follows the pricing formula prescribed under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018. The issue was authorized by a special resolution passed by shareholders on June 17, 2026, and an initial Board approval on May 25, 2026. The committee meeting on July 9, 2026, commenced at 10:10 pm and concluded at 10:25 pm. The filing was submitted to BSE Limited and National Stock Exchange of India Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.